CSL.AX CSL Limited
ASXHealthcareAs of 2026-08-20 02:15
Why CSL.AX matters now
CSL Limited (CSL.AX) is a US stock in Healthcare. The latest InvestLog snapshot shows $171.20 with +2.84% on the session and $81.99B in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E -23.05, gross margin 47.8%, and operating margin 25.6%.
Valuation
P/E (TTM)
-23.05
PEG
—
P/B
3.95
P/S
3.71
EV/EBITDA
13.37
DCF Value
—
FCF Yield
4.8%
Div Yield
2.5%
Margins & Returns
Gross Margin
47.8%
Operating Margin
25.6%
Net Margin
-16.1%
ROE
-15.1%
ROA
-7.5%
ROIC
10.0%
Listing Info
Market
US
Exchange
ASX
Currency
USD
Sector
Healthcare
Industry
Biotechnology
Country
AU
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.